Easton Capital
Easton Capital is a venture capital firm focused on healthcare and life sciences. The firm emphasizes capital-efficient investments that address fundamental unmet medical needs and typically finances companies that require limited additional capital to reach market or become acquisition targets. Easton manages approximately $200 million across several funds and targets investments that it can lead or co-lead while providing financial, strategic and operational support to portfolio companies. (Sources: http://www.eastoncapital.com/overview.html, http://www.eastoncapital.com/index.html)
Industries
Nr. of Employees
small (1-50)
Easton Capital
767 Third Avenue (at 48th St), 7th Floor, New York, NY 10017
Portfolio
Lead asset PRM-151 in Phase 2 for IPF and myelofibrosis; Bristol-Myers Squibb obtained an exclusive right to acquire Promedior under an agreement with potential aggregate payments up to $1.25 billion (announced Aug 31, 2015).
#Therapeutics
Described on the site as a portfolio company developing gene therapy approaches for genetic blood disorders.
#Therapeutics (gene therapy)
Described as a system to reduce medication dispensing mistakes.
#Healthcare IT / patient safety
Included as a case study and listed under Healthcare IT portfolio.
#Healthcare IT / communications
Lead asset PRM-151 in Phase 2 for IPF and myelofibrosis; Bristol-Myers Squibb obtained an exclusive right to acquire Promedior under an agreement with potential aggregate payments up to $1.25 billion (announced Aug 31, 2015).
#Therapeutics
Described on the site as a portfolio company developing gene therapy approaches for genetic blood disorders.
#Therapeutics (gene therapy)
Described as a system to reduce medication dispensing mistakes.
#Healthcare IT / patient safety
Included as a case study and listed under Healthcare IT portfolio.
#Healthcare IT / communications